The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: Three-year follow-up after switching therapy

HIV Clinical Trials

Volumn 8, Issue 6, 2007, Pages 381-390

  Madruga, José Valdez R ^a   Cassetti, Isabel ^b   Suleiman, Jamal Muhamad A H ^c   Etzel, Arnaldo ^d   Zhong, Lijie ^e   Holmes, Charles B ^e   Cheng, Andrew K ^e   Enejosa, Jeffrey ^e  

^a Centro de Referencia e Treinamento DST/AIDS   (Brazil)

^b Centro de Estudios Infectologicos   (Argentina)

^c Brasilmed Assistência Médica e Pesquisas   (Brazil)

^d Hospital Guilherme Alvaro   (Brazil)

^e GILEAD SCIENCES   (United States)

Author keywords

Antiretroviral therapy; Lamivudine; Stavudine; Switch; Tenofovir

Indexed keywords

CHOLESTEROL; EFAVIRENZ; LAMIVUDINE; RNA; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADENINE; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; BENZOXAZINES; BRAZIL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DOMINICAN REPUBLIC; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHOSPHONIC ACIDS; PLACEBOS; STAVUDINE; TRIGLYCERIDES; VIRAL LOAD;

EID: 37349062681     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0806-381     Document Type: Article

References (30)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining mortality and morbidity in HIV-infected ambulatory patients. New Engl J Med. 1998;338:853-860.
2. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; October 10, 2006. Available at: http://AIDSinfo.nih.gov.
3. Palella FJ, Moorman AC, Chmiel J, Chan C, Holmberg SD, HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy (ART) for ambulatory HIV-infected patients. AIDS. 2002;16:1617-1627.
4. Heath K, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-239.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS. 1998;12:F51-58.
6. Carr A, Hudson J, Chau J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: randomised, controlled, open-label multi-centre study. AIDS. 2001;15:1811-1822.
7. Martin A, Smith DE, Ringland C, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS. 2004;18:1029-1036.
8. McComsey GA, Ward DJ, Hesssenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270.
9. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
10. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
11. Moyle G, Sabin C, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
12. Milinkovic A, Lopez S, Vidal S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther. 2007;12(3):407-415.
13. Moreno S, Domingo P, Elias MJP, et al. Identification and follow-up of adverse events related to NRTI use that in the clinical practice cause their substitution by tenofovir DF (48 week data from the RECOVER study). Presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
14. Ribera E, Paradineiro JC, Sauleda S, et al. Improvements in subcutaneous fat, lipid profile and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
15. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429-438.
16. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naïve patients: a 3 year randomized trial. JAMA. 2004;292:191-201.
17. Hammer SM, Saag MS, Schechter M, et al. International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296(7):827-843.
18. Cassetti I, Madruga JVR, Suleiman JMAH, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164-172.
19. National Institutes of Allergy and Infectious Diseases. Division of AIDS Table of Grading Severity of Adult Adverse Experiences. August 1992. Available at: http://rcc.tech-res-intl.com.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
21. Levy S, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Int Med. 1999;130:461-470.
22. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. N Engl J Med. 2006;3:251-260.
23. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-1263.
24. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139:313-320.
25. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir-containing highly active antiretroviral therapy regimens: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489-1495.
26. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared to nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1197.
27. Gallant JE, Parish MA, Keruly JC, Moore RD. Tenofovir and changes in renal function: reply to Gupta [Letter]. Clin Infect Dis. 2005;41:571.
28. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologie, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535-540.
29. Gayet-Ageron A, Ananworanich J, Jupimai T, et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother. 2007;59(5):1034-1037.
30. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement [online]. 2000 March 27-29;17(1):1-36. Available at: http://consensus.nih.gov/2000/2000Osteoporosis11html.htm